Definitive Healthcare (NASDAQ:DH – Get Free Report) had its price target dropped by investment analysts at Barclays from $4.00 to $3.00 in a report issued on Monday,Benzinga reports. The brokerage presently has an “underweight” rating on the stock. Barclays‘s price objective indicates a potential downside of 7.12% from the stock’s previous close.
Several other equities analysts have also recently issued reports on the company. Stephens started coverage on Definitive Healthcare in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.00 price objective for the company. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $5.61.
Definitive Healthcare Trading Down 34.3 %
Definitive Healthcare (NASDAQ:DH – Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.04). The business had revenue of $62.29 million during the quarter, compared to analysts’ expectations of $60.60 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. Sell-side analysts anticipate that Definitive Healthcare will post 0.16 EPS for the current year.
Insider Transactions at Definitive Healthcare
In related news, insider William Moschella sold 45,000 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $4.70, for a total value of $211,500.00. Following the transaction, the insider now directly owns 433,830 shares of the company’s stock, valued at approximately $2,039,001. This trade represents a 9.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 14.84% of the company’s stock.
Hedge Funds Weigh In On Definitive Healthcare
A number of hedge funds have recently made changes to their positions in the company. Irenic Capital Management LP increased its position in shares of Definitive Healthcare by 9.2% during the fourth quarter. Irenic Capital Management LP now owns 7,003,194 shares of the company’s stock worth $28,783,000 after purchasing an additional 590,009 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Definitive Healthcare by 36.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 6,053,233 shares of the company’s stock worth $27,058,000 after buying an additional 1,626,813 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Definitive Healthcare by 1.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,863,912 shares of the company’s stock valued at $7,661,000 after buying an additional 23,410 shares during the last quarter. State Street Corp lifted its stake in shares of Definitive Healthcare by 29.4% in the third quarter. State Street Corp now owns 1,399,729 shares of the company’s stock worth $6,257,000 after buying an additional 317,952 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Definitive Healthcare by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 1,272,660 shares of the company’s stock worth $5,231,000 after acquiring an additional 39,938 shares during the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.
Definitive Healthcare Company Profile
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.
See Also
- Five stocks we like better than Definitive Healthcare
- Why is the Ex-Dividend Date Significant to Investors?
- These 3 Tech Stocks Are Gaining Steam After NVIDIA’s Report
- Low PE Growth Stocks: Unlocking Investment Opportunities
- These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- One Value, One Growth, and One Momentum Stock For Diversification
Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.